


VALTRESX[®] Tablets

NAME OF THE MEDICINE: Valaciclovir

DESCRIPTION: Valaciclovir is the L-valine ester of aciclovir. Its chemical name is 2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy]ethyl L-valinate hydrochloride. Aciclovir is a purine nucleoside analogue.



Chemical formula: C₁₃H₂₀N₆O₄.HCl

Molecular weight: 360.8

CAS Number: 124832-27-5

Valtrex tablets contain the active ingredient valaciclovir. The tablets also contain microcrystalline cellulose, crospovidone, povidone, colloidal anhydrous silica, carnauba wax, magnesium stearate, white colour concentrate, and blue printing ink.

PHARMACOLOGY:

Mode of Action

Valaciclovir is rapidly and almost completely converted in man to aciclovir probably by the enzyme valaciclovir hydrolase. Aciclovir is a specific inhibitor of the herpes viruses with *in vitro* activity against herpes simplex viruses (HSV) type 1 and type 2 (IC₅₀ 0.1 – 3.0µM), varicella-zoster virus (VZV) (IC₅₀ 1.6 – 5.1µM) and human cytomegalovirus (HCMV) (IC₅₀ 10 - > 200µM). Aciclovir inhibits herpes virus DNA synthesis once it has been phosphorylated to the active triphosphate form. The first stage of phosphorylation requires the activity of a virus-specific enzyme: thymidine kinase in HSV and VZV infected cells or protein kinase in HCMV infected cells. This requirement for activation of aciclovir by a virus specific enzyme

largely explains its unique selectivity. The phosphorylation process is completed (conversion from mono- to triphosphate) by cellular kinases. Aciclovir triphosphate competitively inhibits the virus DNA polymerase and incorporation of this nucleoside analogue results in obligate chain termination, halting virus DNA synthesis and thus blocking virus replication.

PHARMACOKINETIC PROPERTIES:

General characteristics

After oral administration valaciclovir is well absorbed and rapidly and almost completely converted to aciclovir and valine. This conversion is probably mediated by valaciclovir hydrolase, an enzyme isolated from human liver. Mean peak aciclovir concentrations are 10-37 μM (2.2 – 8.3 $\mu\text{g/mL}$) following single doses of 250-2000 mg valaciclovir to healthy subjects with normal renal function and occur at a median time of 1.00 – 2.00 hours post dose. The time to peak (T_{max}) is 1.6 hours for 2 x 500 mg tablets and 1.9 hours for a 1000 mg tablet. The bioavailability of aciclovir following a dose of 1000 mg of valaciclovir is 54% and is unaffected by food. Peak plasma concentrations of valaciclovir are only 4% of aciclovir levels, occur 30 – 100 minutes post dose, and are at or below the limit of quantification 3 hours after dosing. Binding of aciclovir to plasma proteins is very low (9 to 33 %).

Acyclovir maximum concentration (C_{max}) and area under the acyclovir concentration-time curve (AUC) after single-dose administration of 100 mg, 250 mg, 500 mg, 750 mg, and 1 gram of VALTREX to 8 healthy volunteers resulted in the mean C_{max} (\pm SD) of 0.83 (\pm 0.14), 2.15 (\pm 0.50), 3.28 (\pm 0.83), 4.17 (\pm 1.14), and 5.65 (\pm 2.37) mcg/mL, respectively; and a mean AUC (\pm SD) of 2.28 (\pm 0.40), 5.76 (\pm 0.60), 11.59 (\pm 1.79), 14.11 (\pm 3.54), and 19.52 (\pm 6.04) hr•mcg/mL, respectively.

Similarly acyclovir C_{max} and AUC after the multiple-dose administration of 250 mg, 500 mg, and 1 gram of VALTREX administered 4 times daily for 11 days in parallel groups of 8 healthy volunteers resulted in a mean C_{max} (\pm SD) of 2.11 (\pm 0.33), 3.69 (\pm 0.87), and 4.96 (\pm 0.64) mcg/mL, respectively, and a mean AUC (\pm SD) of 5.66 (\pm 1.09), 9.88 (\pm 2.01), and 15.70 (\pm 2.27) hr•mcg/mL, respectively.

In patients with normal renal function the plasma elimination half-life of aciclovir after both single and multiple dosing with valaciclovir is approximately 3 hours. In patients with end-stage renal disease, the average elimination half-life of aciclovir after valaciclovir administration is approximately 14 hours. Less than 1% of the administered dose of

valaciclovir is recovered in the urine as unchanged drug. Valaciclovir is eliminated principally as aciclovir (greater than 80% of the recovered dose) and the known aciclovir metabolite, 9-(carboxymethoxy) methylguanine (CMMG), in the urine.

Characteristics in patients

The pharmacokinetics of valaciclovir and aciclovir are not altered significantly in patients with herpes zoster and herpes simplex infections after oral administration of Valtrex.

CLINICAL TRIALS:


Herpes Zoster Infections:

Two doses of valaciclovir were compared to aciclovir in a double blind randomised trial in immunocompetent patients aged 50 years and over with herpes zoster (n=1141). All patients were treated within 72 hours of the appearance of the rash. Valaciclovir 1 g three times daily for seven days achieved statistically significant reductions in the duration of zoster-associated pain (which is the sum of acute pain and post-herpetic neuralgia) and in the duration of post-herpetic neuralgia when compared with aciclovir. There was no statistically significant difference between the three treatments for the resolution of rash.

	Median duration (days)		
	valaciclovir		aciclovir
	1 g three times daily		800 mg five times daily
	for 7 days (n=384)	for 14 days (n=381)	for 7 days (n=376)
All Zoster associated Pain (Z-aP)	38	44	51
Post Herpetic Neuralgia (PHN)	30	35	39

There was no significant difference to the duration of zoster-associated pain when treatment was started within 48 hours or 72 hours. Patients treated within 48 hours of rash onset were found to have faster healing rates as measured by the duration of new lesion formation and time to crusting or healing of 50 % or more of lesions. Thus, greater benefit is gained if the drug is started within 48 hours.

Duration of Zoster-associated Pain: Kaplan-Meier Plots for Valaciclovir versus Aciclovir for Patients ≥ 50 years old



NOTE: ACV-7 – acyclovir at 800mg five times daily for 7 days; VACV-7 – valaciclovir at 1000mg three times daily for 7 days;

VACV-14 – valaciclovir at 1000mg three times daily for 14 days

In a second, placebo controlled trial in patients under 50 years of age (n=399), demonstration of efficacy was restricted to a small decrease in mean time to cessation of new lesion formation. No significant effects were demonstrated for other outcomes of herpes zoster in this age group. Nevertheless, the occasional younger patients with severe herpes zoster may benefit from therapy with valaciclovir. Herpes zoster is usually a milder condition in younger patients.

In ophthalmic zoster oral aciclovir has been shown to reduce the incidence of stromal keratitis and both the incidence and severity of anterior uveitis but not other ocular complications or acute pain. The recommended dose of valaciclovir produces higher plasma concentrations of aciclovir than those associated with these beneficial effects.

Cold Sores (Herpes Labialis):

Two double-blind, placebo-controlled clinical trials were conducted in 1,856 healthy immunocompetent adults and adolescents (≥12 years old) with a history of recurrent cold sores. Patients self-initiated therapy at the earliest symptoms and prior to any signs of a cold sore. The majority of patients initiated treatment within 2 hours of onset of symptoms.

The two trials investigated the clinician based duration of episode and prevention/blockage of cold sore lesion development as diametrically opposed primary and secondary endpoints.

Patients were randomised in to 3 groups: Valtrex 2 grams twice daily for one day OR Valtrex 2 grams twice daily for one day, followed by 1 gram twice daily on day 2, OR placebo on both days.

An integrated analysis of both trials showed a statistically significant prevention/blockage of onset of lesions in 44% of patients on one day therapy compared to 37% receiving placebo. The mean duration of cold sores in the integrated analysis showed a significant reduction in duration of approximately 1 day when compared to placebo. The ITT population showed the mean duration of episodes was 6.2 days in the placebo group, and 5.2 days in the 1 day group giving a treatment difference of -1.0 day (CI -1.4, -0.6).

The single study results showed the mean duration of cold sore episodes was approximately 1 day shorter in treated subjects when compared to placebo. For the ITT population, when tested as the primary endpoint, the mean duration of episodes was 6.1 days in the placebo group and 5.0 days in the 1 day group, giving a treatment difference of -1.1 days (CI -1.6, -0.6). When tested as the secondary endpoint, For the ITT population, the mean duration of episodes was 6.3 days in the placebo group and 5.3 days in the 1 day group, giving a treatment difference of -1.0 days (CI -1.5, -0.5).

The onset of lesions was prevented in the 43 – 44% of patients on one day VALTREX therapy compared with 35-38% placebo treated patients. No significant difference was observed between subjects receiving VALTREX or Placebo in the prevention of progression of cold sore lesions beyond the papular stage when tested as the primary or secondary endpoint.

There are no data on the effectiveness of treatment initiated after the development of clinical signs of a cold sore i.e. papule, vesicle or ulcer. The 2 day regimen did not offer additional benefit over the 1-day regimen.

The data are based on treatment of a single episode of herpes labialis.

Acute treatment of Initial and Recurrent Herpes Simplex Virus (HSV) Infections:

Four large multicentre, randomised double-blind trials were conducted in adults with herpes simplex infections. These studies included a total of 3569 treated patients of whom 1941 received valaciclovir.

Initial genital herpes simplex infections: One study compared valaciclovir (1000 mg twice daily) with aciclovir (200 mg five times daily) administered for 10 days in immunocompetent patients with initial (primary or first episode) genital herpes. Patients reported to the clinic for treatment within 72 hours of the first signs or symptoms of genital

herpes.

Patients were randomized to receive Valtrex (n=323) or Zovirax (n=320) for 10 days. The median time to lesion healing was 9 days in each treatment group. The median time to the cessation of viral shedding was 3 days in each treatment group. Median time to cessation of pain was 5 days in each treatment group.

Recurrent genital herpes simplex infections: The other three studies enrolled immunocompetent patients with a history of recurrent genital herpes infections. These studies compared valaciclovir (1000 mg and/or 500 mg twice daily) with aciclovir (200 mg five times daily) and/or placebo, administered for 5 days. Patients self-initiated therapy within 24 hours of the first sign or symptom of a recurrent genital herpes episode.

The primary efficacy end-points in each study were:

- lesions healing time and pain/discomfort.
- proportions of patients in whom lesions were prevented (aborted lesions).
- viral shedding.

In one study, patients were randomized to receive five days of treatment with either valaciclovir 500 mg bid (n=360) or placebo (n=259). **Duration of lesions:** The median time to lesion healing was four days in the group receiving valaciclovir 500 mg versus six days in the placebo group. **Cessation of viral shedding:** The median time to cessation of viral shedding in patients with at least one positive culture (42 % of the overall study population) was two days in the group receiving valaciclovir 500 mg versus four days in the placebo group. **Cessation of pain:** The median time to cessation of pain was three days in the group receiving valaciclovir 500 mg versus four days in the placebo group. Results supporting efficacy were replicated in the other two studies. **Prevention of lesion development (Aborted episodes):** Pooled analysis of the three studies also showed that the use of valaciclovir in patients who self-initiated treatment in the prodrome, increased the chances of preventing lesion development (aborting episodes) by 31% to 44 % compared with placebo.

Prevention of Recurrent Genital Herpes Simplex Virus (HSV) infections:

Three large, multicentre, double-blind, randomised trials were conducted to investigate the efficacy of valaciclovir for the prevention of recurrent genital HSV infection. Two studies evaluated the disease in immunocompetent individuals, while the third evaluated an immunocompromised (HIV-infected) population.

Immunocompetent patients:

The two trials conducted in immunocompetent patients included a total of 1861 patients, of which 1366 received valaciclovir for up to 52 weeks. The primary endpoint in both trials was defined as the first clinical recurrence of HSV infection, and the proportion recurrence free at the end of 12 months was another endpoint. In Study BQRT/95/0026, 500mg once daily treatment with valaciclovir was compared with placebo in patients with a history of at least 8 recurrences per year. Clinical recurrence was defined as lesions reaching the papule/vesicle stage, and valaciclovir delayed or prevented 85% of the recurrences compared with placebo.

Study BQRT/96/0001 was a double blind study comparing a variety of valaciclovir doses and aciclovir with placebo. Clinical recurrence was defined as lesions at the macule/papule stage. As HSV infection had been identified as a strong prognostic factor in previous genital herpes studies, subgroup analyses was conducted according to recurrence history. The results from the proportional hazards analyses (hazard ratios and 95% CI) for the active treatment comparisons with placebo obtained within each subgroup are presented below:

HSV Recurrence Frequency	Comparison	Hazard Ratio	95% Confidence Interval
<10	VACV 250mg bd vs PBO	0.122	(0.083, 0.181)
	VACV 1000mg od vs PBO	0.160	(0.110, 0.231)
	VACV 500mg od vs PBO	0.182	(0.128, 0.258)
	VACV 250mg od vs PBO	0.319	(0.227, 0.448)
	ACV 400mg bd vs PBO	0.160	(0.109, 0.234)
≥10	VACV 250mg bd vs PBO	0.325	(0.226, 0.468)
	VACV 1000mg od vs PBO	0.274	(0.188, 0.400)
	VACV 500mg od vs PBO	0.451	(0.308, 0.659)
	VACV 250mg od vs PBO	0.632	(0.446, 0.895)
	ACV 400mg bd vs PBO	0.261	(0.181, 0.378)

Results show that 250mg twice daily offered the best clinical efficacy for suppression of genital herpes recurrences in this group of patients. However, the same total daily dose given as single daily dose (i.e. 500mg once daily) was also very effective, as confirmed with Study BQRT/95/0026.

Although 1000mg daily was more effective than 500mg once daily in the first study, the marginal difference between the two did not justify long term exposure to double the daily dose. The hazard ratio comparing valaciclovir 1000mg once daily and 500mg once daily

indicated an increase in efficacy of only approximately 12% (hazard ratio 0.879, 95% CI 0.637, 1.211).

Immunocompromised patients:

A third study examined a total of 1062 immunocompromised patients (HIV-infected, CD₄⁺ counts of $\geq 100/\text{mm}^3$ at enrolment) of whom 713 received valaciclovir (1000 mg once daily, 500mg twice daily, 48 weeks) compared with 349 patients who received aciclovir (400 mg twice daily, 48 weeks). The primary endpoint was the time to first HSV recurrence (onset of macules/papules). The study demonstrated that valaciclovir 500 mg twice daily is as effective as aciclovir in preventing or delaying HSV infections in immunocompromised patients. Valaciclovir 500 mg twice daily was significantly more efficacious than valaciclovir 1000 mg once daily.

Reduction of Genital Herpes Simplex Virus transmission

Study HS2AB3009 was a randomised, double blind, placebo controlled trial evaluating valaciclovir 500mg once daily for eight months in the prevention of HSV-2 transmission in heterosexual monogamous couples. 1484 couples received treatment with 741 source partners receiving placebo and 743 source partners receiving valaciclovir. Source partners had to be seropositive for HSV-2 and have a history of recurrent genital herpes with less than 10 recurrences per year. Susceptible partners could not be seropositive for HSV-2, but could be seropositive for HSV-1. Couples were encouraged to practice safer sex (including use of condoms). The primary endpoint of the study was the proportion of couples that developed clinical evidence of a first episode of genital herpes HSV-2 in the susceptible partner. Clinical evidence of a first episode was defined as symptomatic genital herpes confirmed by laboratory analysis.

The results of this study established that the proportion of couples with clinical symptoms of genital herpes in the susceptible partner was higher in the placebo group than in the valaciclovir group (2.2% vs. 0.5% respectively). The risk of transmission of symptomatic genital herpes was reduced by 75% (95% CI 26%, 92%, $p=0.011$) in the valaciclovir group, a difference which is both clinically and statistically significant.

The results of the time to event analysis confirm those of the primary endpoint, with the time to clinical symptoms being significantly longer in the valaciclovir group compared with the placebo group ($p=0.008$).

The proportion of couples with overall acquisition* of genital HSV-2 infection in the susceptible partner was 3.6% (27/741) in the placebo group and 1.9% (14/743) in the

valaciclovir group ($p=0.054$, approximate relative risk (95% CI): 0.52 (0.27, 0.97). These analyses show that there was a 48% reduction in the risk of acquiring HSV-2 infection in the valaciclovir group compared with the placebo group. This difference approached statistical significance for overall acquisition.

(* Overall Acquisition: in which the susceptible partner acquired genital herpes HSV-2 infection, as documented by HSV-2 seroconversion only, or by seroconversion and/or detection of the virus by culture or PCR, and irrespective of the presence of clinical symptoms).

The result of the analysis of time to overall acquisition of HSV-2 (Hazard Ratio: 0.52; 95% CI: 0.27, 0.99), which explicitly allows for differential length of follow-up, is statistically significant ($p=0.039$).

The proportion of couples with HSV-2 seroconversion in the susceptible partner was 3.2% (24/741) in the placebo group and 1.6% (12/743) in the valaciclovir group ($p=0.060$, approximate relative risk (95% CI): 0.50 (0.25, 0.99)).

The proportion of couples with asymptomatic seroconversion in the susceptible partner was 1.5% (11/741) in the placebo group and 1.3% (10/743) in the valaciclovir group ($p=0.996$, approximate relative risk (95% CI): 0.91 (0.39, 2.12)).

Valaciclovir was effective in reducing the risk of genital HSV-2 recurrence in source partners (the proportion of source partners with a genital HSV-2 recurrence was: placebo: 573/724, 79%; valaciclovir: 288/715, 40%), with the time to first recurrence being significantly longer in the valaciclovir group compared with the placebo group ($p<0.001$; hazard ratio 0.30, 95% CI 0.26, 0.35).

The incidence of the primary endpoint was higher in the female susceptible partners than in the male susceptible partners. The proportion of female susceptible partners in whom clinical evidence of first episode genital HSV-2 infection was reported was 4.1% (10/244) in the placebo group and 0.8% (2/244) in the valaciclovir group. The proportion of male susceptible partners in whom clinical evidence of first episode genital HSV-2 infection was reported was 1.2% (6/497) in the placebo group and 0.4% (2/499) in the valaciclovir group.

The safety profile of valaciclovir in this study was similar to that of placebo, and to that demonstrated previously for this dosing regimen in a similar population.

Prophylaxis of cytomegalovirus (CMV) infection and disease, following organ transplantation:

Three double-blind, randomised clinical studies were conducted to investigate the efficacy and safety of valaciclovir in the prophylaxis of CMV infection and disease following renal or heart transplantation. These studies included a total of 643 patients, of whom 320 received valaciclovir, 13 received aciclovir and 310 received placebo.


The primary efficacy endpoint in renal transplant studies was the development of CMV disease and the primary endpoint in the heart transplant study was the development of CMV antigenaemia. Secondary endpoints for the studies included CMV disease (heart transplant study), CMV infection, reduced acute graft rejection, fewer opportunistic bacterial or fungal infections and reduced herpes virus disease (HSV, VZV).

Renal Transplant Studies

The two renal transplant studies involved a total of 616 renal transplant recipients, of which 306 received a daily dose of 2 g valaciclovir four times daily (adjusted according to creatinine clearance for renal function) and 310 received placebo for 90 days. The patients were stratified by donor and recipient CMV-serostatus (seropositive recipients [R+] versus seronegative recipients of a graft from a seropositive donor [D+R-]). Patients commenced study drug within 72 hours post-transplant and continued treatment for 90 days (treatment period) receiving, following adjustment for renal function, a daily average dose of 4.7g ([R+] subjects) and 5.3g ([D+R-] subjects) valaciclovir. Patients were evaluated for efficacy and safety for six months post-transplant (study period).

In renal transplant recipients valaciclovir was significantly better than placebo in preventing or delaying CMV disease by 78% and 82% in the [D+R-] and [R+] strata respectively, during the six month study period.

Proportions of patients [D+R-] without confirmed CMV disease: Kaplan-Meier plots for Valaciclovir versus Placebo



Valaciclovir was also significantly better than placebo in preventing or delaying the development of viraemia, viruria and clinical HSV disease during the study period. No valaciclovir recipient developed VZV disease, whereas 2% and 4% of placebo patients did, R+ and D+R- strata respectively. Additionally in D+R- patients, valaciclovir was shown to significantly reduce acute graft rejections (biopsy proven and clinical acute rejection by 57% and 45% respectively) and opportunistic infections (48% primarily bacterial and fungal infections). There were no significant differences in rates of chronic graft rejection. Allograft function and survival, including the proportion of patients with a functional graft at their last assessment were similar between treatment groups. Administration of valaciclovir was associated with significantly fewer hospital admissions and reduced use of ganciclovir and aciclovir for the treatment of CMV disease or other herpes virus infections, respectively.

Heart transplant study

The third study enrolled 27 heart transplant recipients. This study compared valaciclovir (n = 14, 2 g four times daily, adjusted according to creatinine clearance for renal function) with aciclovir (n = 13, 200 mg four times daily). Treatment was commenced within 3 days post-transplant and continued for 90 days. Patients were followed up until the end of the sixth month.

During the 90 day treatment period, 29% of patients on valaciclovir developed CMV antigenaemia (primary endpoint) compared to 92% of patients who received aciclovir. The time difference to CMV antigenaemia was statistically significant, with median time to CMV antigenaemia of 19 vs. 119 days in favour of valaciclovir (HR=0.422, 95%CI: 0.179, 0.992; p=0.049). At the end of the study period (3 months following the treatment period) the proportion of patients with CMV antigenaemia was similar in both treatment arms.

Notable but not statistically significant reductions in the rates of CMV infection (valaciclovir 43%, aciclovir 92%), symptomatic CMV infection (valaciclovir 0%, aciclovir 38%), CMV disease (valaciclovir 0%, aciclovir 23%) and HSV disease (valaciclovir 29%, aciclovir 54%), were observed during the 90 day treatment period. The incidence of other infections (bacterial, fungal, non-herpes virus) was also lower in the valaciclovir group throughout the entire study period (valaciclovir 36%, aciclovir 62%). There were no significant differences in graft rejection and survival rates between the valaciclovir and aciclovir patients at the end of the study (3 months following treatment period).

Results for the primary and secondary endpoints in the pivotal trials

Endpoints	Renal [D+ R-]			Renal [R+]			Heart		
	Hazard Ratio	95% CI	p-value	Hazard Ratio	95% CI	p-value	Hazard Ratio	95% CI	p-value
CMV disease	0.22	0.12, 0.40	< 0.0001	0.18	0.04, 0.83	<0.027	0.19	0.02, 1.70	0.09
CMV antigenaemia	n/d	n/d	n/d	n/d	n/d	n/d	0.42	0.18, 0.99	0.049
CMV infection	n/d	n/d	n/d	n/d	n/d	n/d	0.46	0.20, 1.06	0.075
CMV viraemia	0.25	0.14, 0.44	<0.0001	0.28	0.18, 0.45	<0.0001	n/d	n/d	n/d
CMV viruria	0.49	0.32, 0.76	0.001	0.32	0.24, 0.44	<0.0001	n/d	n/d	n/d
Acute graft rejection									
- biopsy proven	0.43	0.27, 0.83	0.001	0.86	0.60, 1.03	0.40	0.51	0.22, n/d	0.09
- clinical	0.55	0.37, 0.76	0.004	0.75	0.55, 1.03	0.073	n/d	1.19, n/d	n/d
Opportunistic infections	0.52	0.36, 0.76	0.001	0.90	0.70, 1.16	0.41	(0.42)*	NP	NP
HSV disease	0.33	0.15, 0.74	0.007	0.16	0.09, 0.30	<0.0001	n/d	n/d	n/d
VZV disease	Did not develop			Did not develop			Did not develop		

Results based on entire study period (3 months treatment followed by 3 months follow up)

* odds ratio in brackets

n/d = not done

NP = not protocolled

Bone Marrow transplant studies

Two additional clinical studies have been conducted to assess the safety and efficacy of Valtrex in the prophylaxis of CMV infection in bone marrow transplant recipients. The adverse event data from these trials is consistent with the current safety profile of valaciclovir.

INDICATIONS:

For the treatment of herpes zoster (shingles) in adult patients who commence therapy within 72 hours of the onset of rash.

For the treatment of ophthalmic zoster.

For the treatment of recurrent herpes labialis (cold sores)

For the treatment of clinical episodes of genital herpes simplex infections.

For the prevention of recurrent genital herpes.

Reduction of transmission of genital herpes in patients suffering from recurrent genital herpes. In addition to therapy with Valtrex, it is recommended that patients use safer sex practices. (**See PRECAUTIONS**).

Prophylaxis of cytomegalovirus (CMV) infection and disease following solid organ transplantation in patients at risk of CMV disease.

CONTRAINDICATIONS:

Valtrex is contraindicated in patients known to be hypersensitive to valaciclovir, aciclovir or any component of the formulation.

PRECAUTIONS:

Thrombotic thrombocytopenic purpura or haemolytic uraemic syndrome, in some cases resulting in death, has occurred in patients with advanced HIV disease who were treated with valaciclovir for prolonged periods and also in allogenic bone marrow transplant and renal transplant recipients who were treated with valaciclovir while participating in clinical trials at doses of 8 grams per day.

Similar signs have been observed in patients with the same underlying or concurrent conditions who were not treated with valaciclovir.

Use of valaciclovir at doses of 1000mg/day in immunocompromised patients with CD4⁺ counts > 100x10⁶L has not been associated with occurrences of thrombotic microangiopathy (TMA). However use in severely immunocompromised patients (CD4⁺ counts < 100x10⁶L) has not been examined at this low dosage.

Mutagenic Potential

Valaciclovir was not mutagenic in bacterial cells nor did it demonstrate any clastogenic potential *in vitro* in human lymphocytes or *in vivo* in the rat bone marrow assay. The mouse micronucleus assay was negative at 250 mg/kg but weakly positive at 500 mg/kg. Valaciclovir, at concentrations ≥ 2000 $\mu\text{g/mL}$ in the presence of S9 metabolic activation was mutagenic in the mouse lymphoma assay. The active metabolite, aciclovir, was clastogenic in Chinese hamster cells *in vivo*, at exposure levels also causing nephrotoxicity (500 & 1000 mg/kg parenteral dose). There was also an increase, though not statistically significant, in chromosomal damage at maximum tolerated doses (100 mg/kg) of aciclovir in rats. No activity was found in a dominant lethal study in mice or in 4 microbial assays. Positive results were obtained in 2 of 7 genetic toxicity assays using mammalian cells *in vitro* (positive in human lymphocytes *in vitro* and one locus in mouse lymphoma cells, negative at 2 other loci in mouse lymphoma cells and 3 loci in a Chinese hamster ovary cell line).

The results of these mutagenicity tests *in vitro* and *in vivo* suggest that valaciclovir and aciclovir are unlikely to pose a genetic threat to man at therapeutic dose levels.

Carcinogenic Potential

The data presented below include references to the steady-state aciclovir AUC observed in humans treated with 1 gram Valtrex given orally three times a day to treat herpes zoster (HZV) or with 2 gram Valtrex given orally four times a day to treat cytomegalovirus (CMV). Plasma drug concentrations in animal studies are expressed as multiples of human exposure to aciclovir.

Valaciclovir was noncarcinogenic in lifetime carcinogenicity bioassays at oral doses of up to 120 mg/kg/day for mice and 100 mg/kg/day for rats. There was no significant difference in the incidence of tumours between treated and control animals, nor did valaciclovir shorten the latency of tumours. Plasma concentrations (AUC) of aciclovir were equivalent to 1.1 (HZV) and 0.1 times (CMV) human levels in the mouse bioassay and 1.3 (HZV) and 0.1

(CMV) times human concentrations in the rat bioassay.

Effects on Fertility

Valaciclovir did not impair fertility or reproduction in rats at 200mg/kg per day, corresponding to plasma levels 2.8 (HZV) and 0.3 (CMV) times human plasma concentrations (AUC).

Use in Pregnancy (Category B3)

Valaciclovir was not teratogenic in rats or rabbits given oral doses of 400 mg/kg (which results in exposures of 1.1 and 2.0 times (HZV) and 0.4 and 0.7 times (CMV) human exposure, respectively, based on body surface area) during the period of major organogenesis. Aciclovir was not teratogenic in the mouse (450 mg/kg PO), rabbit (50 mg/kg SC and IV) or rat (50 mg/kg SC) when dosed throughout the period of organogenesis. Plasma concentrations of aciclovir in the rat were 3.5 (HZV) and 0.8 (CMV) times human concentrations. In additional studies in which rats were given three SC doses of 100 mg/kg aciclovir on gestation day 10, foetal abnormalities, such as head and tail anomalies, were reported. Plasma concentrations of aciclovir in the rat were 19 (HZV) and 4.3 (CMV) times human concentrations.

There are no adequate and well-controlled studies of Valtrex or Zovirax in pregnant women. A prospective epidemiologic registry of aciclovir use during pregnancy has been ongoing since June 1984. Pregnancy registries have documented the pregnancy outcomes in women exposed to valaciclovir or to any formulation of aciclovir (the active metabolite of valaciclovir); 111 and 1246 outcomes (29 and 756 exposed during the first trimester of pregnancy), respectively, were obtained from women prospectively registered. Registry findings do not indicate an increased risk of major birth defects after aciclovir exposure ~~ie~~ in comparison with the general population. The accumulated case histories represent an insufficient sample for reaching reliable and definitive conclusions regarding the risk associated with aciclovir exposure during pregnancy. The daily aciclovir AUCs (area under plasma concentration-time curve) following Valtrex 1000mg and 8000mg daily would be approximately 2 and 9 times greater than that expected with oral aciclovir 1000mg daily, respectively.

There are limited data on the use of Valtrex in pregnancy. Valtrex should only be used in pregnancy if the potential benefit outweighs the potential risk.

Use in Lactation

Lactating rats given a 25 mg/kg PO dose of ¹⁴C-valaciclovir showed peak milk radioactivity levels of 26 µg/eq/g, 2 hours post dose. The milk radioactivity levels declined slower than in

plasma, and were undetectable at 12 hours. Suckling pups had radioactivity in the stomach and intestinal contents up to 7 hours post dose, but not in tissues.

Limited data show that aciclovir does pass into human breast milk. In a study conducted on 5 women, following oral administration of a 500 mg dose of valaciclovir, peak aciclovir concentrations (C_{max}) in breast milk ranged from 0.5 to 2.3 (median 1.4) times the corresponding maternal aciclovir serum concentrations. The aciclovir AUC was 2.2 times (range 1.4 to 2.6) higher in breast milk compared to maternal serum. In other studies, conducted with oral acyclovir administration, aciclovir had been detected in breast milk at concentrations ranging from 0.6 to 4.1 times the corresponding aciclovir plasma concentration. Caution is therefore advised if Valtrex is to be administered to a breast-feeding mother. Valtrex should only be administered to breast-feeding mothers if the benefits to the mother outweigh the potential risks to the baby.

Use in Children

Safety and effectiveness in children have not been established.

Hydration Status

Care should be taken to ensure adequate fluid intake in patients who are at risk of dehydration, particularly the elderly.

Information for Patients

Patients should be informed that Valtrex (or any other antiviral) is not a cure for genital herpes. Because genital herpes is a sexually transmitted disease, patients should avoid contact with lesions or intercourse when lesions and/or symptoms are present to avoid infecting partners. Genital herpes can also be transmitted in the absence of symptoms through asymptomatic viral shedding.

Use in Cold Sores (Herpes Labialis)

Patients should be advised to initiate treatment at the earliest symptom of a cold sore (e.g. tingling, itching, or burning). There are no data on the effectiveness of treatment initiated after the development of clinical signs of a cold sore (e.g. papule, vesicle, or ulcer). Patients should be instructed that treatment for cold sores should not exceed 1 day (2 doses) and that their doses should be taken 12 hours apart. Patients should be informed that Valtrex is not a cure for cold sores (*herpes labialis*).

Use in genital herpes

Continuous therapy with Valtrex in patients with recurrent genital herpes reduces the risk of

transmitting genital herpes. It does not cure genital herpes or completely eliminate the risk of transmission. In addition to therapy with Valtrex, it is recommended that patients use safer sex practices.

Driving

No special precautions necessary.

A detrimental effect on driving or ability to operate machinery can not be predicted from the pharmacological properties of valaciclovir or the active substance aciclovir. No studies to investigate the effect of valaciclovir on such activities have been conducted. However, the clinical status of the patient and the adverse event profile of valaciclovir should be borne in mind when considering a patient's ability to drive or operate machinery.

Use in patients with renal impairment

The dose of valaciclovir must be reduced in patients with renal impairment (see Dosage and Administration). Aciclovir delivered by valaciclovir is eliminated by renal clearance (see Pharmacology). Patients with renal impairment are at increased risk of developing neurological side effects and should be closely monitored for evidence of these effects. In the reported cases, these reactions were generally reversible on discontinuation of treatment (see Adverse Reactions).

Use in the elderly

Elderly patients are likely to have reduced renal function and therefore the need for dose reduction must be considered in this group of patients. Elderly patients are at increased risk of developing neurological side effects and should be closely monitored for evidence of these effects. In the reported cases, these reactions were generally reversible on discontinuation of treatment (see Adverse Reactions).

Reversible neurological reactions including dizziness, confusion, hallucinations, rarely decreased consciousness and very rarely tremor, ataxia, dysarthria, convulsions, encephalopathy and coma have been reported. These events are usually seen in patients with renal impairment or with other predisposing factors. In organ transplant patients receiving high doses (8g daily) of Valtrex for CMV prophylaxis, neurological reactions occurred more frequently compared with lower doses.

Use of high dose Valtrex in hepatic impairment and liver transplantation

There are no data available on the use of high doses of Valtrex (8 g/day) in patients with liver disease. Caution should therefore be exercised when administering high doses of Valtrex to these patients. Specific studies of Valtrex have not been conducted in liver

transplantation; however high dose aciclovir has been studied in this population.

Interactions with other drugs

No clinically significant interactions have been identified.

Aciclovir is eliminated primarily unchanged in the urine via active renal tubular secretion. Any drugs administered concurrently that compete with this mechanism may increase aciclovir plasma concentrations following valaciclovir administration.

Following 1g valaciclovir, cimetidine and probenecid increase the AUC of aciclovir by this mechanism, and reduce aciclovir renal clearance. However, no dosage adjustment is necessary at this dose because of the wide therapeutic index of aciclovir.

In patients receiving high-dose valaciclovir (8g/day) for CMV prophylaxis, caution is required during concurrent administration with drugs which compete with aciclovir for elimination, because of the potential for increased plasma levels of one or both drugs or their metabolites. Increases in plasma AUCs of aciclovir and of the inactive metabolite of mycophenolate mofetil, an immunosuppressant agent used in transplant patients, have been shown when the drugs are co-administered.

Care is also required (with monitoring for changes in renal function) if administering high-dose valaciclovir with drugs which affect other aspects of renal physiology (eg cyclosporin, tacrolimus).

ADVERSE REACTIONS:

Valaciclovir was well tolerated when used for the treatment of herpes zoster and genital herpes in clinical trials. The most commonly reported adverse experiences were headache and nausea and these were reported in a similar proportion of patients on valaciclovir, aciclovir and placebo.

Herpes Zoster Infections:

The following table lists all adverse events reported during a six month observation period in immunocompetent patients receiving short-term treatment (7 or 14 days) with valaciclovir and reference products in controlled clinical trials.

	% Incidence of adverse events	
Patient age group	≥ 50 years	18 to 50 years

	valaciclovir 1 g 3 x daily (n=765) 14 days n=381 7 days n=384	aciclovir 800 mg 5 x daily 7 days (n=376)	valaciclovir 1 g 3 x daily 7 days (n=202)	Placebo 7 days (n=197)
Nausea	16.5	19.1	9.9	7.6
Headache	12.9	12.8	16.8	11.7
Vomiting	6.8	7.7	4.5	2.5
Diarrhoea	5.5	7.4	4.5	6.1
Constipation	5.1	5.3	1.5	2.5
Asthenia	4.4	5.3	3.0	3.6
Dizziness	3.7	5.9	2.0	2.0
Abdominal Pain	3.3	2.7	2.5	1.5
Anorexia	3.0	2.7	0.5	2.0
Dyspepsia	2.5	1.9	-	-
Dry mouth	1.8	0.5	-	-
Flatulence	1.8	1.6	-	-
Fever	1.4	2.4	-	-
Insomnia	1.6	0.5	-	-
Rhinitis	1.3	1.6	1.5	1.5
Chills	1.0	1.6	-	-
Back Pain	1.0	0.5	-	-
Nervousness	1.0	0.0	-	-
Somnolence	0.9	2.1	-	-
Pain	0.8	1.6	-	-
Rash	0.7	1.9	-	-
Myalgia	-	-	0.5	2.5
Infection	-	-	2.0	1.0

HSV Infections:

Initial and recurrent genital herpes (short term treatment):

The adverse events reported by greater than 2% of a given treatment group in the initial and recurrent genital herpes clinical trials with valaciclovir and reference products used in the trials are listed in the following table:

Patient age group	% Incidence of adverse events		
	17 - 79 years		
	Valaciclovir	aciclovir	Placebo

	1 g 2 x daily (n=1203) 10 days n=323 5 days n=880 500 mg 2 x daily 5 days (n=738)	200 mg 5 x daily 5 days (n=1187)	(n=441)
Headache	16	11	14
Nausea	6	7	7
Diarrhoea	4	3	6
Dizziness	3	2	2
Abdominal pain	2	3	2
Asthenia	2	2	4
Rhinitis	2	2	2
Pharyngitis	1	2	1
Pain	1	1	2
Dyspepsia	1	1	2
Vomiting	1	2	0
Back pain	1	1	2

Prevention of genital herpes (long-term preventative therapy):

The adverse events reported at an incidence of 5% or greater in a given treatment group, in clinical trials for the preventative treatment of genital herpes with valaciclovir and reference products, are listed in the following table:

% Incidence of adverse events						
	Immunocompetent				Immunocompromised	
	V 500mg 1 x daily 52 weeks n=266	V 250mg 2 x daily 52 weeks n=274	A 400mg 2 x daily 52 weeks n=267	PBO 52 weeks n=134	V 500mg 2 x daily 48 weeks n = 355	A 400mg 2 x daily 48 weeks n = 349
Headache	38	35	37	34	18	17
Rhinitis	23	26	25	18	13	14
Infection	18	15	21	16	16	13
Flu syndrome	12	20	18	13	7	7
Pharyngitis	12	8	11	14	11	13

Nausea	11	9	12	8	16	12
Back Pain	8	12	13	6	6	7
Diarrhoea	9	8	12	14	19	19
Abdominal Pain	9	9	7	6	12	7
Pain	11	6	8	4	6	6
Sinusitis	8	7	12	5	7	7
Accidental Injury	7	7	10	3	3	5
Dysmenorrhoea	5	8	8	4	-	-
Dyspepsia	3	6	7	8	3	4
Rash	5	5	6	7	14	14
Arthralgia	5	5	7	4	3	3
Depression	5	5	4	5	9	7
Allergic Reaction	6	6	4	4	-	-
Urinary Tract Infection	5	2	7	2	-	-
Bronchitis	5	4	5	2	3	7
Myalgia	5	4	8	2	3	5
Asthenia	4	5	3	5	8	9
Tooth Disorder	5	3	4	3	1	3
Unevaluable Reaction	5	3	5	2	3	4
Migraine	4	4	5	2	-	-
Acne	3	4	3	3	5	3
Dizziness	2	5	3	1	2	3
Insomnia	5	3	1	2	3	4
Vomiting	3	3	5	2	7	5
Pruritus	2	3	2	1	5	3
Increased Coughing	3	4	1	2	6	10
Fever	3	1	1	1	11	11
Rectal Disorder	-	-	-	-	4	5

V = Valaciclovir

A = Aciclovir

PBO = Placebo

Prophylaxis of cytomegalovirus (CMV) infection and disease, following organ transplantation.

Valaciclovir was well tolerated in the clinical studies of renal and heart transplant patients. The nature and frequency of adverse events were similar between placebo, aciclovir and valaciclovir treated patients, with the exception of adverse events relating to the CNS

(hallucinations, confusion and thinking abnormality). These were reported more frequently in valaciclovir than placebo in renal transplant patients. The most common adverse events reported in the renal transplant patients were anaemia, hypertension and headache. Headache and myalgia were the most common adverse events reported in the heart transplant patients. All the clinical adverse events occurring at an incidence of $\geq 5\%$ or $\geq 20\%$ in a given treatment group, in clinical trials for CMV prophylaxis following renal and heart transplants respectively are listed in the following tables.

Summary of all adverse events reported at an incidence $\geq 5\%$ by renal transplant recipients in clinical trials for CMV prophylaxis.

Adverse Event	Renal Transplant Recipients	
	Valaciclovir* (n = 306)	Placebo (n = 310)
Anaemia	12%	12%
Hypertension	11%	8%
Headache	9%	11%
Diarrhoea	9%	12%
Abdominal Pain	8%	11%
Leukopenia	8%	8%
Hallucination	8%	1%
Fever	8%	11%
Nausea	8%	7%
Vomiting	8%	7%
Peripheral Oedema	8%	9%
Confusion	7%	2%
Dyspnoea	7%	5%
Pain	7%	7%
Constipation	7%	5%
Insomnia	6%	3%
ALT** increase	5%	6%
Thrombocytopenia	5%	5%
Pruritus	5%	2%

Summary of all adverse events reported at an incidence $\geq 20\%$ by heart transplant recipients in clinical trials for CMV prophylaxis.

Adverse Event	Heart Transplant Recipients	
	Valaciclovir* (n = 14)	Aciclovir (n = 13)
Headache	57%	62%
Myalgia	57%	46%
Cough increase	57%	46%
Peripheral Oedema	50%	62%
Asthenia	43%	15%
Effus Pericard	43%	46%
Pain	43%	31%
Dyspnoea	36%	38%
Back Pain	29%	15%
Nausea	21%	23%
Insomnia	21%	15%
General Oedema	21%	54%
Hypertension	21%	38%
Somnolence	21%	23%
Constipation	21%	15%
Depression	21%	15%
Sleep Disorder	21%	15%
Chest Pain	21%	-
Dizziness	7%	31%

Summary of all adverse events reported at an incidence \geq 5% by renal transplant recipients in clinical trials for CMV prophylaxis.

Adverse Event	Renal Transplant Recipients	
	Valaciclovir* (n = 306)	Placebo (n = 310)
Arthralgia	5%	6%
Tremor	4%	6%
Oedema	4%	5%
AST*** increase	4%	6%

* The dosage adjustment of valaciclovir (and aciclovir) in the renal and heart transplant clinical studies differed.

** ALT = alanine aminotransferase.

*** AST = aspartate aminotransferase.

Cold Sores (Herpes Labialis):

In clinical studies for the treatment of cold sores, the adverse events reported by patients receiving Valtrex (n = 609) or placebo (n = 609) included headache (Valtrex 14%, placebo 10%) and dizziness (Valtrex 2%, placebo 1%). The frequencies of abnormal ALT ($>2 \times$ ULN) were 1.8 % for patients receiving Valtrex compared with 0.8% for placebo. Other laboratory abnormalities (haemoglobin, white blood cells, alkaline phosphatase and serum creatinine) occurred with similar frequencies in the 2 groups.

Other Adverse Reactions

The following adverse events have been observed in clinical practice with valaciclovir:

Gastrointestinal tract:

Common - nausea, abdominal discomfort, vomiting and diarrhoea

Haematological:

Rare – thrombocytopenia.

Very rare – leukopenia*, thrombotic microangiopathy (TMA) (refer to PRECAUTIONS).

Summary of all adverse events reported at an incidence \geq 20% by heart transplant recipients in clinical trials for CMV prophylaxis.

Adverse Event	Heart Transplant Recipients	
	Valaciclovir * (n = 14)	Aciclovir (n = 13)
Diarrhoea	7%	23%
Mouth Ulcer	-	23%

*Leukopenia is mainly reported in immunocompromised patients

Hypersensitivity, skin and subcutaneous tissue disorders:

Uncommon - rashes including photosensitivity

Rare - pruritus, dyspnoea, and anaphylaxis

Very rare - urticaria, angioedema

Immune system disorders:

Very rare – anaphylaxis

Kidney:

Rare - renal impairment.

Very rare – reports of acute renal failure, renal pain

Renal pain may be associated with renal failure

Liver:

Rare - reversible increases in liver function tests, occasionally described as hepatitis.

Neurological/psychiatry:

Common - headache.

Rare - decreased consciousness* dizziness*, confusion* and hallucinations*

Very rare - coma*, agitation*, tremor*, ataxia*, dysarthria*, psychotic symptoms*, convulsions*, encephalopathy*

*usually in patients with renal impairment or with other predisposing factors. In organ transplant patients receiving high doses of Valtrex for CMV prophylaxis, neurological reactions occurred more frequently compared with lower doses.

Respiratory, thoracic and mediastinal disorders:

Uncommon – dyspnoea

There have been reports of renal insufficiency, microangiopathic haemolytic anaemia and thrombocytopenia (sometimes in combination) in severely immunocompromised patients, particularly those with advanced HIV disease, receiving high doses (8 g daily) of valaciclovir for prolonged periods in clinical trials. These findings have been observed in patients not treated with valaciclovir who have the same underlying or concurrent conditions.

DOSAGE AND ADMINISTRATION:

Dosage in Adults

For treatment of herpes zoster, 1000 mg of Valtrex three times a day for seven days.

The recommended dosage of Valtrex for the treatment of cold sores is 2000 mg twice daily for 1 day with the second dose taken about 12 hours (no sooner than 6 hours) after the first dose. Therapy should be initiated at the earliest symptom of a cold sore (e.g. tingling, itching, or burning)

For treatment of first clinical presentation of genital herpes, 500 mg of Valtrex twice a day for 5 to 10 days. For recurrent episodes of genital herpes, 500 mg twice daily for 5 days.

Dosing should begin as early as possible. For recurrent episodes of genital herpes, this should ideally be during the prodromal period or immediately following the appearance of the first signs or symptoms.

For the prevention of genital herpes in patients with a history of fewer than 10 recurrences each year, 500mg of valaciclovir once daily, either as a single dose or a divided dose (see Clinical Trials section).

For the prevention of genital herpes in patients with a history of 10 or more recurrences each year when not taking suppressive therapy, 1000mg of valaciclovir once daily.

For immunocompromised patients, 500 mg twice daily.

Reduction of transmission of genital herpes:

In immunocompetent heterosexual adults with less than 10 recurrences per year and with the susceptible partner discordant for HSV-2 antibodies, 500mg of Valtrex to be taken once daily by the infected partner.

There are no data on the reduction of transmission in other patient populations.

For the prophylaxis of cytomegalovirus infection (CMV) and disease.

Dosage in adults and adolescents (from 12 years of age)

The dosage of Valtrex is 2 g four times a day for 90 days, to be initiated as early as possible post-transplant. This dose should be reduced according to creatinine clearance (see Dosage in renal impairment).

Dosage in renal impairment

Caution is advised when administering Valtrex to patients with impaired renal function. Adequate hydration should be maintained.

Treatment of herpes zoster and genital herpes simplex: The dose of Valtrex should be modified as follows in patients with significantly impaired renal function:

Creatinine Clearance	Valtrex Dose				
	Herpes Zoster	Genital Herpes Simplex			
		Treatment	Prevention		Reduction of Transmission of genital herpes
			Immuno-competent	Immuno-compromised	
15-30 mL/min	1000 mg twice a day	No modification required	No modification required	No modification required	No modification required
< 15 mL/min	1000 mg once a day	500 mg once daily	250 mg once daily	500 mg once daily	250 mg once daily

Treatment of herpes labialis: The dose of Valtrex should be modified as follows in patients with significantly impaired renal function:

Creatinine Clearance	Valtrex dose
≥ 50 mL/min	2000 mg twice a day
31 – 49mL/min	1000 mg twice a day
15-30 mL/min	500 mg twice a day
< 15 mL/min	500 mg single dose

In patients on haemodialysis the Valtrex dose recommended for patients with a creatinine clearance of less than 15 mL/min should be used, but the dose should be administered after the haemodialysis has been performed.

CMV prophylaxis: The dosage of Valtrex should be adjusted in patients with impaired renal function as shown in the table below:

Creatinine clearance ml/min	Valtrex dosage
75 or greater	2 g four times daily
50 to less than 75	1.5 g four times a day
25 to less than 50	1.5 g three times a day
10 to less than 25	1.5 g twice a day
less than 10 or dialysis [◇]	1.5 g once a day

[◇] In patients on haemodialysis, the Valtrex dosage should be administered after the haemodialysis has been performed.

The creatinine clearance should be monitored frequently, especially during periods when renal function is changing rapidly e.g. immediately after transplantation or engraftment. The Valtrex dosage should be adjusted accordingly.

Dosage in hepatic impairment

Studies with a 1 g unit dose of Valtrex show that dose modification is not required in patients with mild or moderate cirrhosis (hepatic synthetic function maintained). Pharmacokinetic data in patients with advanced cirrhosis, (impaired hepatic synthetic function and evidence of portal-systemic shunting) do not indicate the need for dosage adjustment; however clinical experience is limited. For higher doses recommended for CMV prophylaxis **see Warnings and Precautions.**

Dosage in children

No data are available.

Dosage in the elderly

The possibility of renal impairment in the elderly must be considered and the dosage should be adjusted accordingly (**see Dosage in renal impairment**). Adequate hydration should be maintained.

Dosage in special patient groups

No dosage recommendations.

Monitoring advice

No special monitoring necessary.

Instructions for use

No special instructions for use.

OVERDOSAGE:**Symptoms and signs**

Acute renal failure and neurological symptoms, including confusion, hallucinations, agitation, decreased consciousness and coma, have been reported in patients receiving overdoses of valaciclovir. Nausea and vomiting may also occur. Caution is required to prevent inadvertent overdosing. Many of the reported cases involved renally impaired and elderly patients receiving repeated overdoses, due to lack of appropriate dosage reduction.

Management

Patients should be observed closely for signs of toxicity. Haemodialysis significantly enhances the removal of aciclovir from the blood and may, therefore, be considered a management option in the event of symptomatic overdose.

PRESENTATION AND STORAGE:

*Biconvex, elongated white film-coated tablets with a white to off-white core, branded Valtrex 250, containing 250 mg valaciclovir. Blister packs of 60.

Biconvex, elongated white film-coated tablets with a white to off-white core, branded GX CF1, containing 500 mg valaciclovir. Blister packs of 2*, 4*, 6*, 8, 10, 20*, 30, 42, 60*, 80*, 90*, 100, 240* and 480*. Bottles of 8*, 100*, 240*, 480* and

500*.

Biconvex, elongated white film-coated tablets with a white to off-white core, branded Valtrex 1000 on one side and scored on the other, containing 1000 mg valaciclovir. Blister packs of 3*, 4 and 21*. Bottles of 4*, 100* and 250*.

* Presentations not currently marketed.

Storage conditions:

Store below 30°C

NAME AND ADDRESS OF THE SPONSOR:

GlaxoSmithKline Australia Pty Ltd
1061 Mountain Highway
Boronia Victoria 3155

Date of TGA approval: 12 August 2008.

Valtrex® is a trade mark of the GlaxoSmithKline Group of Companies.

